RESUMO
Fabry disease (FD) is a progressive multisystemic lysosomal storage disease. Early diagnosis by newborn screening (NBS) may allow for timely treatment, thus preventing future irreversible organ damage. We present the results of 5.5 years of NBS for FD by α-galactosidase A activity and globotriaosylsphingosine (lyso-Gb3) assays in dried blood spot through a multiplexed MS/MS assay. Furthermore, we report our experience with long-term follow-up of positive subjects. We screened more than 170,000 newborns and 22 males were confirmed to have a GLA gene variant, with an incidence of 1:7879 newborns. All patients were diagnosed with a variant previously associated with the later-onset phenotype of FD or carried an unclassified variant (four patients) or the likely benign p.Ala143Thr variant. All were asymptomatic at the last visit. Although lyso-Gb3 is not considered a reliable second tier test for newborn screening, it can simplify the screening algorithm when its levels are elevated at birth. After birth, plasma lyso-Gb3 is a useful marker for non-invasive monitoring of all positive patients. Our study is the largest reported to date in Europe, and presents data from long-term NBS for FD that reveals the current incidence of FD in northeastern Italy. Our follow-up data describe the early disease course and the trend of plasma lyso-Gb3 during early childhood.
Assuntos
Teste em Amostras de Sangue Seco/métodos , Doença de Fabry/sangue , Doença de Fabry/diagnóstico , Triagem Neonatal/métodos , alfa-Galactosidase/sangue , Teste em Amostras de Sangue Seco/tendências , Doença de Fabry/epidemiologia , Feminino , Seguimentos , Glicolipídeos/sangue , Humanos , Recém-Nascido , Itália/epidemiologia , Masculino , Triagem Neonatal/tendências , Esfingolipídeos/sangue , Fatores de TempoRESUMO
OBJECTIVES: Evidence is mixed regarding the impact of false-positive (FP) newborn bloodspot screening (NBS) results on health care use. Using cystic fibrosis (CF) as an example, we determined the association of FP NBS results with health care use in infants and their mothers in Ontario, Canada. METHODS: We conducted a population-based cohort study of all infants with FP CF results (N = 1564) and screen-negative matched controls (N = 6256) born between April 2008 and November 2012 using linked health administrative data. Outcomes included maternal and infant physician and emergency visits and inpatient hospitalizations from the infant's third to 15th month of age. Negative binomial regression tested associations of NBS status with outcomes, adjusting for infant and maternal characteristics. RESULTS: A greater proportion of infants with FP results had >2 outpatient visits (16.2% vs 13.2%) and >2 hospital admissions (1.5% vs 0.7%) compared with controls; CF-related admissions and emergency department visits were not different from controls. Differences persisted after adjustment, with higher rates of outpatient visits (relative risk 1.39; 95% confidence interval 1.20-1.60) and hospital admissions (relative risk 1.67; 95% confidence interval 1.21-2.31) for FP infants. Stratified models indicated the effect of FP status was greater among those whose primary care provider was a pediatrician. No differences in health care use among mothers were detected. CONCLUSIONS: Higher use of outpatient services among FP infants may relate to a lengthy confirmatory testing process or follow-up carrier testing. However, increased rates of hospitalization might signal heightened perceptions of vulnerability among healthy infants.
Assuntos
Fibrose Cística/sangue , Fibrose Cística/diagnóstico , Teste em Amostras de Sangue Seco/normas , Triagem Neonatal/normas , Aceitação pelo Paciente de Cuidados de Saúde , Adulto , Estudos de Coortes , Fibrose Cística/epidemiologia , Teste em Amostras de Sangue Seco/tendências , Reações Falso-Positivas , Feminino , Humanos , Lactente , Recém-Nascido , Masculino , Triagem Neonatal/tendências , Ontário/epidemiologia , Vigilância da População , Estudos RetrospectivosRESUMO
Blood testing using the dried blood spot (DBS) is used since the 1960s in clinical analysis, mainly within the framework of the neonatal screening (Guthrie test). Since then numerous analytes such as nucleic acids, small molecules or lipids, were successfully measured on the DBS. While this pre-analytical method represents an interesting alternative to classic blood sampling, its use in routine is still limited. We review here the different clinical applications of the blood sampling on DBS and estimate its future place, supported by the new methods of analysis as the LC-MS mass spectrometry.
Assuntos
Coleta de Amostras Sanguíneas/métodos , Coleta de Amostras Sanguíneas/tendências , Teste em Amostras de Sangue Seco , Proteínas Sanguíneas/análise , Carboidratos/análise , Carboidratos/sangue , Teste em Amostras de Sangue Seco/métodos , Teste em Amostras de Sangue Seco/tendências , Genômica/métodos , Humanos , Lipídeos/análise , Lipídeos/sangue , Ácidos Nucleicos/análise , Ácidos Nucleicos/isolamento & purificação , Peptídeos/análise , Peptídeos/sangue , Xenobióticos/análise , Xenobióticos/sangueRESUMO
IP-10 is a small pro-inflammatory chemokine secreted primarily from monocytes and fibroblasts. Alterations in IP-10 levels have been associated with inflammatory conditions including viral and bacterial infections, immune dysfunction, and tumor development. IP-10 is increasingly recognized as a biomarker that predicts severity of various diseases and can be used in the immunodiagnostics of Mycobacterium tuberculosis and cytomegalovirus infection. Here, we describe an ELISA-based method to detect IP-10 from dried blood and plasma spot samples.